ABSTRACT
Lipomas are benign mesenchymal tumours that are rarely seen in the scrotum. Few cases of primary scrotal lipomas originating from the scrotal wall have been reported in the literature. We describe the case of a giant primary intrascrotal lipoma presenting as scrotal swelling and discomfort. Findings from scrotal magnetic resonance imaging were highly suspicious for lipoma. The mass was completely excised and histological examination confirmed the diagnosis of lipoma.
Subject(s)
Genital Neoplasms, Male/diagnosis , Lipoma/diagnosis , Scrotum/pathology , Genital Neoplasms, Male/pathology , Genital Neoplasms, Male/surgery , Humans , Lipoma/pathology , Lipoma/surgery , Magnetic Resonance Imaging/methods , Male , Middle Aged , Scrotum/surgeryABSTRACT
Benign prostatic hyperplasia is considered a progressive disease intimately linked with aging. The long-term use of combination therapy with a 5-alpha-reductase inhibitor, together with an alpha blocker in men with moderate-severe symptoms, reduces the risk of clinical progression and BPH-related surgery. It is unclear what the impact is of preoperative therapy with 5-ARI in patients that undergo surgery. The aim of our study was to evaluate the impact of preoperative therapy with 5-alpha-reductase inhibitors on: a) indication on the type of surgery; b) surgical and functional outcomes; c) surgical complications. This is a prospective observational study. It will include all patients undergoing surgery by TURP or Open Prostatectomy in a period of 24 months. We expect results that demonstrate significant and favorable influence of pretreatment with 5-alpha-reductase inhibitors on certain outcomes. Therefore, therapy with 5-ARI could be considered as neoadjuvant to surgery, whatever this is.
Subject(s)
5-alpha Reductase Inhibitors/therapeutic use , Adrenergic alpha-Antagonists/therapeutic use , Clinical Trials as Topic/methods , Neoadjuvant Therapy , Prostatic Hyperplasia/drug therapy , 5-alpha Reductase Inhibitors/administration & dosage , Adrenergic alpha-Antagonists/administration & dosage , Drug Therapy, Combination , Humans , Male , Outcome Assessment, Health Care , Patient Selection , Prospective Studies , Prostatectomy , Prostatic Hyperplasia/surgery , Research Design , Transurethral Resection of ProstateABSTRACT
The Morris syndrome is a X-linked recessive condition due to a complete or partial insensitivity to androgens, resulting in a failure of normal masculinization of the external genitalia in chromosomally male individuals. This failure of virilization can be either complete or partial depending on the amount of residual androgen receptor function. The phenotype of individuals with partial androgen insensitivity syndrome may range from mildly virilized female external genitalia to mildly undervirilized male external genitalia. We describe a case of Partial Androgen Insensitivity Syndrome in a 21-year-old patient with a 46, XY karyotype, bilateral inguinal masses, clitoral enlargement and partial posterior labial fusion. Surgical care consisted of bilateral orchiectomy and plastic surgery of external genitalia. The patient underwent estrogen replacement therapy.
